Significance of transesophageal contrast echocardiography with the agitated saline test for diagnosing pulmonary arteriovenous malformations

Kyoung Hee Lim1†, Sung Mok Kim2†, Sung-Ji Park3*, Eun Kyoung Kim3, Sung-A Chang3, Sang-Chol Lee3, Seung Woo Park3 and Yeon Hyeon Choe2

1Division of Cardiology, Department of Internal Medicine, Dong-A University Hospital, Busan, South Korea, 2Department of Radiology, Imaging Center, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, 3Division of Cardiology, Department of Internal Medicine, Imaging Center, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea

Objectives: This study evaluated the diagnostic value of transesophageal contrast echocardiography (TECE) with the agitated saline test for diagnosing pulmonary arteriovenous malformations (PAVMs) in comparison with chest CT or pulmonary angiography.

Background: Although transthoracic contrast echocardiography (TTCE) is the recommended screening test for diagnosing PAVMs, it has low specificity and positive predictive value. TECE is expected to offer improved sensitivity and specificity compared with TTCE, but no studies have reported the diagnostic accuracy and clinical significance of TECE in detecting PAVMs.

Methods and results: In total, 1,809 patients underwent TECE with the agitated saline test to evaluate symptoms of a suspected right to left shunt. Patients with hereditary hemorrhagic telangiectasia (HHT) were excluded. A total of 387 patients showed transpulmonary bubble passage, indicating a PAVM. Among them, 182 patients had additional chest CT or pulmonary angiography. Those patients were divided into two groups according to the presence of a PAVM in the radiologic imaging. A total of 18 patients (9.8%) were confirmed for the PAVM group. Only 13 patients required embolization for their PAVMs. The TECE with saline test results were divided into four grades according to the number of bubbles: grade 1 (n = 91), grade 2 (n = 47), grade 3 (n = 35), and grade 4 (n = 9). None of the patients in the PAVM group had grade 1 shunts in their TECE results. The positive predictive values for the presence of a PAVM according to the TECE grade scale were 10.6% for grade 2, 22.8% for grade 3, and 55.6% for grade 4.

Conclusion: TECE with a grade scale is a useful method for initially diagnosing PAVMs in non-HHT patients with a suspected right to left shunt. The findings
of this study also suggest that patients with a small grade (<10 bubbles) shunt in their TECE findings should be spared unnecessary radiation exposure from CT scans or pulmonary angiography.

**KEYWORDS**
pulmonary arteriovenous malformation, transesophageal echocardiography, cerebral infarction, shunt, idiopathic

### Introduction

Pulmonary arteriovenous malformations (PAVMs) are pulmonary vascular anomalies that enable capillary-free communication between the pulmonary artery and pulmonary vein (1). PAVMs are mostly hereditary, and approximately 90% of them are associated with hereditary hemorrhagic telangiectasia (HHT) (2–4). Although PAVMs are rare, untreated PAVMs contribute to complications, such as paradoxical arterial embolization, stroke, cerebral abscess, hypoxemia, migraine, and hemorrhage (5–7). Previous studies have already established effective screening tests for PAVM diagnosis in asymptomatic HHT patients. Transthoracic contrast echocardiography (TTCE) has high sensitivity (93–100%) for detecting PAVMs (3, 8–10). Because complications associated with PAVMs also occur in even asymptomatic patients without HHT and because PAVMs can be effectively treated by percutaneous transcatheter embolization (11), the diagnosis of PAVMs that form an intrapulmonary right-to-left shunt in patients without HHT is important.

In patients suspected to have PAVMs, TTCE with the agitated saline test is recommended as the initial screening modality instead of chest CT or diagnostic pulmonary angiography (1, 12). In TTCE with the agitated saline test, the delayed appearance of bubbles in the left atrium (LA), more than three to five cardiac cycles after initial opacification of the right atrium, is considered to indicate an extracardiac shunt, including PAVMs (13). However, the presence of PAVMs is not confirmed by the introduction of bubbles from the pulmonary vein into the LA in TTCE, which has relatively low specificity for radiographically detectable PAVMs (32–82%) (3, 8, 9). A false positive indication of an extracardiac shunt in TTCE can result in unnecessary radiation exposure from chest CT or pulmonary angiography. Transesophageal contrast echocardiography (TECE) with agitated saline might be a more specific screening diagnostic test for detecting a right to left shunt, though it is a more invasive procedure than TTCE (14). Some studies have already tested TECE with the agitated saline test for the right to left shunt detection (15–17), but no studies have reported the diagnostic accuracy or clinical significance of using TECE with the agitated saline test to detect PAVMs. We hypothesized that TECE with the agitated saline test would be a useful initial screening tool for identifying PAVMs in patients with a suspected right to left shunt because it visualizes transpulmonary bubble passage.

### Materials and methods

**Study population**

We retrospectively investigated 1,809 subjects who underwent TECE with the agitated saline test at Samsung Medical Center between December 2000 and March 2018 for evaluation of symptoms suggestive of a right to left shunt. The Curacao diagnostic criteria were used to distinguish and exclude patients with HHT. Those criteria are recurrent epistaxis, telangiectasia, arteriovenous malformations, and family history of HHT, and an HHT diagnosis is considered definite if three of those conditions are met. None of the patients analyzed in this study were found to have definite HHT. Among the 387 subjects who had the transpulmonary passage of contrast in their TECE results, which suggested the presence of a PAVM, 185 subjects underwent a further imaging study such as chest CT or pulmonary angiography at their clinician’s discretion. The time interval between echocardiography and the further imaging study was less than 120 days in all patients. Patients with an extracardiac shunt (1 porto-left atrium shunt; 1 anomalous origin of the right coronary artery from the left coronary sinus, 1 pulmonary sequestration) and those with patent foramen ovale requiring device closure (n = 8) were excluded. Thus, 182 patients were enrolled in this study and divided into two groups: 18 patients with PAVMs and 164 without PAVMs (Figure 1). The following clinical data were collected: age, sex, underlying disease, smoking history, routine blood lab, transthoracic echocardiography, transesophageal echocardiography, and PAVM embolization.

**Abbreviations:** CT, Computed tomography; HHT, Hereditary hemorrhagic telangiectasia; LA, Left atrium; LV, Left ventricle; PAVM, Pulmonary arteriovenous malformation; PPV, Positive predictive value; TECE, Transesophageal contrast echocardiography; TTCE, Transthoracic contrast echocardiography.
Transthoracic echocardiography and transesophageal echocardiography

The two-dimensional and Doppler echocardiographic examinations were performed in a standard manner (18, 19) using commercially available echocardiographic devices. Standard TECE with the agitated saline test was performed in study patients by an experienced echocardiography specialist with the support of a sonographer. Three-way stopcocks with 10 ml syringes connected to both ends were placed in the patient’s forearm veins. The saline contrast was composed of 8–9 ml of normal saline agitated with 0.5 ml of air and a small amount of the patient’s blood. In the first study with each patient, the agitated saline contrast test was performed during rest in the bicaval view (110° view). The second test was performed with the Valsalva maneuver or coughing in the bicaval view or a 45° view. Then, the saline contrast test was performed without the Valsalva maneuver in the right and left pulmonary vein select view. In each test, the number of cardiac cycles was measured between the full appearance of air bubbles in the right atrium and their appearance in the LA. The number of bubbles and the location of the shunt were also recorded. The number of bubbles in the LA was graded according to a 4-grade system: grade 1, a small amount of contrast or fewer than 10 bubbles; grade 2, a moderate amount of contrast or 10–30 bubbles; grade 3, more than 30 bubbles; grade 4, a shower with extensive contrast in
the LA (Figure 2). The TECE classification of shunt size was based on the grading system for patent foramen ovale (20), which was modified slightly to facilitate the evaluation of shunt size. Our grading system also differentiates the shower grade in accordance with the TTCE grading system, which is another screening test for diagnosing PAVMs (9).

Computed tomography, pulmonary angiography, and embolization

Contrast-enhanced chest CT images with 1-mm reconstructions in the axial and 2-mm reconstructions in the coronal planes were used for analysis. The identification of at least one feeding artery and vein is mandatory for establishing a PAVM diagnosis on CT images (21) and pulmonary angiography. The diameter of the feeding arteries was measured as close as possible to the nidus of the PAVM. Catheter angiography is not performed routinely for diagnosing PAVMs, but it has been generally performed during embolization procedures. We confirmed PAVMs using the non-selective left and right pulmonary arteriography, which was performed through a 5-Fr Pigtail catheter using the right femoral venous approach. Because all patients had symptoms suggestive of a right to left shunt, embolization was used actively in the PAVM group as much as possible. However, for small PAVMs whose nidus was not visible in the radiologic imaging test, meaning that the connection between the artery and vein was only suspected, embolization was not performed. PAVMs that were not treated with embolization all had a feeding artery that was measured to be less than 1 mm. The Nidus and feeding artery size of a PAVM are described in Supplementary Table 1.
Statistical analysis

Continuous variables are presented as medians and interquartile ranges. The Mann-Whitney test was used to compare between two groups. Categorical variables are presented as absolute numbers (n) and percentages (%), and differences were analyzed using the Pearson chi-squared test. A logistic regression analysis was performed to determine the association between the grade of a shunt in the TECE findings and the presence of PAVMs on CT or pulmonary angiography. The positive predictive value (PPV) of each TECE with agitated saline test grade was calculated using the chest CT or pulmonary angiography result as a reference. All tests were two-tailed, and p-values < 0.05 were considered significant. Statistical analysis was performed with SPSS version 23 (IBM Corp., Armonk, NY, United States).

Results

Of the 1,809 subjects who underwent TECE with the agitated saline test who were reviewed in this study, 387 (21.3%) patients had confirmed the presence of transpulmonary bubble passage in their TECE findings, which was considered to indicate the presence of a PAVM. Only the 182 patients who underwent a further image study (chest CT or pulmonary angiography) were finally included in this study and divided into the PAVM group (n = 18) and the non-PAVM group (n = 164). All patients had symptoms suggestive of right to left shunts, such as a PAVM. The main symptomatic reasons for performing TECE with the agitated saline test were stroke (n = 148, 81.3%), transient ischemic attack (n = 13, 7.1%), paradoxical arterial embolism (n = 12, 6.6%), and other, including migraine and hypoxia (n = 9, 4.9%). Further information is provided in Figure 3.

The baseline characteristics and laboratory findings are shown in Table 1. The PAVM group had more female patients (p = 0.001), and there were differences in the proportion of concomitant disease between the PAVM and non-PAVM groups. Malignancy was more frequent in the non-PAVM group [PAVM vs. non-PAVM; 0 (0%) vs. 30 (18.3%), p = 0.047], and the non-PAVM group also had a higher prevalence of dyslipidemia [2 (11.1%) vs. 55 (33.5%), p = 0.062], and history of smoking [2 (11.1%) vs. 52 (31.7%), p = 0.069]. The mean blood creatinine level was lower in the PAVM group than in the non-PAVM group, but all those values were within the normal range. None of the other baseline characteristics differed statistically between the two groups.

Transthoracic echocardiography was performed to evaluate cardiac function and chamber size. Left ventricle (LV) systolic function and size, LV diastolic function (assessed by septal e'), average E/e', LA volume index, and peak tricuspid regurgitation velocity did not differ significantly between the two groups. However, median peak e' wave velocity was greater in the PAVM group than in the non-PAVM group [0.11 (0.09–0.11) vs. 0.09 (0.07–0.11), p = 0.022]. Further transthoracic echocardiographic parameters are summarized in Table 2.

TTCE with the agitated saline test is described in Table 3. The TECE parameters assessed between the PAVM and non-PAVM groups were the number of cardiac onset cycles in the LA, the location of the shunt, and the number of bubbles according to the grade scale (without the Valsalva maneuver). The number of cardiac cycles for bubbles to appear in the LA after fully filling the right atrium was lower in the PAVM group than in the non-PAVM group [3 (2–5) vs. 6 (4–7), p < 0.001]. All but 1 patient with a positive transpulmonary passage of bubbles had confirmed origin in the pulmonary vein. The most common
origin was the left pulmonary vein in both groups [8 (44.4%) vs. 122 (74.8%)], but the proportion of pulmonary vein origin differed slightly between the groups \((p = 0.024)\).

We also analyzed the TECE with an agitated saline grade scale according to the presence of PAVMs in the CT or pulmonary angiography results. The TECE with agitated saline test results indicated that the PAVM group had a higher frequency of high grade transpulmonary bubble passage than the non-PAVM group \((p < 0.001)\). None of the patients in the PAVM group had small grade shunts, whereas the majority of the non-PAVM group had small grade shunts \([N = 91 (55.5\%)]\). Further information is provided in Table 3.

Moreover, the TECE with agitated saline test grade scale was further evaluated to determine whether those findings could predict whether PAVMs would be found in CT or pulmonary angiography and whether patients would need embolization. The relationships among the TECE grade scale, presence of PAVMs in CT or pulmonary angiography, and presence of PAVMs that required embolization are shown in Table 4. The TECE grade scale and presence of PAVMs in chest CT or pulmonary angiography showed a significant positive correlation in our study patients \((p < 0.001)\). Also, there was a significant association between increases in the TECE shunt grade scale and PAVMs requiring embolization, as expected \((p < 0.001)\). Eighteen patients (100%) in the PAVM group had their PAVM locations evaluated through TECE using the pulmonary vein select view. Table 5 shows the comparison of PAVM locations assessed by TECE, CT, and pulmonary

### Table 1: Clinical characteristics and laboratory findings.

| Characteristic       | PAVM group \((n = 18)\) | Non-PAVM group \((n = 164)\) | \(p\) |
|----------------------|--------------------------|-----------------------------|------|
| Male sex, \(n\) (%)  | 3 (16.7%)                | 96 (58.5%)                  | 0.001* |
| Age                  | 45 [41–48]               | 50 [36–69]                  | 0.072 |
| Diabetes mellitus    | 0 (0%)                   | 17 (10.4%)                  | 0.226 |
| Dyslipidemia         | 2 (11.1%)                | 55 (33.5%)                  | 0.062 |
| Liver cirrhosis      | 0 (0%)                   | 4 (2.4%)                    | 1.000 |
| Chronic kidney disease | 1 (5.6%)             | 5 (3%)                      | 0.470 |
| Infection/inflammation | 0 (0%)                | 13 (7.9%)                   | 0.369 |
| Malignancy           | 0 (0%)                   | 30 (18.3%)                  | 0.047* |
| SPN (lung)           | 0 (0%)                   | 18 (11%)                    | 0.223 |
| Smoking history      | 2 (11.1%)                | 52 (31.7%)                  | 0.069 |
| Hemoglobin           | 13 [12.3–13.9]           | 13.6 [12.4–14.9]            | 0.170 |
| Creatinine           | 0.65 [0.58–0.69]         | 0.79 [0.68–0.93]            | 0.002* |

The \(p\)-value denotes statistical significance when comparing the PAVM and non-PAVM groups.

* \(p < 0.05\) by Mann–Whitney test or \(\chi^2\)-test. Data are listed as numbers (percentage of the group) or median and interquartile ranges.

### Table 2: Transthoracic echocardiography parameters.

| Characteristic       | PAVM group \((n = 18)\) | Non-PAVM group \((n = 164)\) | \(p\) |
|----------------------|--------------------------|-----------------------------|------|
| LV end-diastolic dimension, mm | 47.0 [45.9–48.0] | 48.0 [45.0–51.0] | 0.277 |
| LV ejection fraction,% | 64.5 [59.8–68.4] | 64.0 [59.0–68.0] | 0.986 |
| Mitral E velocity, cm/s | 0.74 [0.65–0.87] | 0.71 [0.56–0.82] | 0.313 |
| Mitral A velocity, cm/s | 0.54 [0.46–0.59] | 0.60 [0.49–0.76] | 0.061 |
| E/A ratio            | 1.47 [1.20–1.68]         | 1.09 [0.84–1.53]            | 0.029* |
| Medial e' velocity, cm/s | 0.11 [0.09–0.11] | 0.09 [0.07–0.11] | 0.022* |
| Medial E/e'           | 7.3 [6.4–8.2]            | 8.5 [6.5–9.8]               | 0.068 |
| LA volume index, mL/m² | 27.6 [22.6–34.5] | 29.9 [25.8–35.1] | 0.170 |

The \(p\)-value denotes statistical significance when comparing the PAVM and non-PAVM groups.

* \(p < 0.05\) by Mann–Whitney test or \(\chi^2\)-test. Data are listed as numbers (percentage of the group) or median and interquartile ranges.

PAVM, pulmonary arteriovenous malformation; SPN, solitary pulmonary nodule.
TABLE 3 Transesophageal contrast echocardiography with agitated saline test parameters.

| Characteristic                  | PAVM group (n = 18) | Non-PAVM group (n = 164) | p     |
|---------------------------------|---------------------|--------------------------|-------|
| Number of cardiac onset cycles  | 3 [2–5]             | 6 [4–7]                  | <0.001*|
| Origin                          |                     |                          | 0.024*|
| Right pulmonary vein            | 5 (27.8%)           | 22 (13.5%)               |       |
| Left pulmonary vein             | 8 (44.4%)           | 122 (74.8%)              |       |
| Both pulmonary veins            | 5 (27.8%)           | 19 (11.7%)               |       |
| Grade scale                     |                     |                          | <0.001*|
| Small (grade 1, < 10)           | 0 (0%)              | 91 (55.5%)               |       |
| Moderate (grade 2, 10–30)       | 5 (27.8%)           | 42 (25.6%)               |       |
| Large (grade 3, > 30)           | 8 (44.4%)           | 27 (16.5%)               |       |
| Shower (grade 4)                | 5 (27.8%)           | 4 (2.4%)                 |       |

The p-value denotes statistical significance when comparing the PAVM and non-PAVM groups.
*P < 0.05 by Mann-Whitney test or χ²-test. Data are listed as numbers (percentage of the group) or median and interquartile ranges.

angiography. All the recorded characteristics of the PAVM group are described in Supplementary Table 1. The TECE results of five patients (27.8%) confirmed the presence of a PAVM in the right lung, and all of them underwent embolization of PAVMs in the right lung. The TECE results of eight patients (44.4%) indicated PAVMs in the left lung, and half of them received embolization for those PAVMs. Only one patient was found to have PAVMs in both pulmonary veins in their radiologic imaging study results. Because of the small size or obscure nidus of their PVAMs, embolization was not performed in five patients in the PAVM group.

**Interobserver variability**

Of the 182 study patients, 10 patients were randomly selected to evaluate the interobserver variability in the TECE grades assigned by two senior sonographers. In the interobserver variability analysis, the Pearson correlation coefficients were greater than 1.0 (Kappa 1.0).

**Discussion**

This single-center, retrospective study analyzed patients who underwent both TECE with the agitated saline test and a radiologic imaging study (chest CT or pulmonary angiography) to evaluate symptoms of a suspected right to left shunt. HHT patients were excluded. Although only 182 patients were finally enrolled, 1,809 cases of TECE with the agitated saline test were reviewed. This study reports the predictive value of TECE with the agitated saline test compared with chest CT or pulmonary angiography for diagnosing PAVMs. The major findings of this study are as follows: (1) Among patients who received TECE with the agitated saline test to diagnose a suspected right to left shunt, a considerable number of patients (21.3%) had positive TECE findings. (2) The non-PAVM group had a higher incidence of malignancy, dyslipidemia, and history of smoking than the PAVM group. (3) The PPV of TECE for the presence of PAVMs was 9.8% in non-HHT patients using the chest CT or pulmonary angiography result as a reference, and the TECE grade scale increased the PPV of the inspection. (4) None of the patients with a small shunt (< 10 bubbles) on their TECE findings showed a PAVM on chest CT or pulmonary angiography.

TTCE with the agitated saline test has been widely used as an initial screening technique for diagnosing PAVMs (1). Several studies have examined the performance of TTCE with the agitated saline test for diagnosing PAVMs and found that it had high sensitivity and negative predictive value (3, 6–9). However, most studies compared the diagnostic value of TTCE with chest CT for finding PAVMs in HHT patients (6–9, 13, 22, 23). Also, it is often difficult to differentiate between an intracardiac shunt and an extra-cardiac shunt when using TTCE in clinical practice, which results in low specificity and PPV. TTCE is not effective enough as an imaging modality to prevent unnecessary radiation exposure through chest CT or pulmonary angiography when diagnosing PAVMs. TECE with the agitated saline test, which provides more accurate images, can be used as a screening test to diagnose the presence of PAVMs. To our knowledge, no previous studies have examined TECE with the agitated saline test for diagnosing PAVMs or considered the

**TABLE 4 Relationship between the TECE grade scale and the presence of PAVMs in CT or pulmonary angiography and PAVMs that required embolization.**

| TECE grade scale | Number | Presence of PAVMs in CT or pulmonary angiography, n (%) | p      | Requiring embolization, n (%) | p      |
|------------------|--------|----------------------------------------------------------|--------|-------------------------------|--------|
| Small (<10)      | 91     | 0 (0%)                                                   | <0.001*| 0 (0%)                        | <0.001*|
| Moderate (10–30) | 47     | 5 (10.6%)                                                | 2 (4.3%)|                               |        |
| Large (>30)      | 35     | 8 (22.8%)                                                | 6 (17.1%)|                               |        |
| Shower           | 9      | 5 (55.6%)                                                | 5 (55.6%)|                               |        |

*P < 0.05 by chi-square test for trend. Data are listed as numbers (percentage of the group).
PAVMs, pulmonary arteriovenous malformations; TECE, transesophageal contrast echocardiography; CT, computed tomography.
TABLE 5 Comparison of PAVM locations assessed by TECE, a radiologic imaging study (chest CT or pulmonary angiography), and embolization.

| Location                  | TECE Number | Chest CT or pulmonary angiography | Number | Embolization | Number |
|---------------------------|-------------|-----------------------------------|--------|--------------|--------|
| Right pulmonary vein      | 5           | Right                             | 5 (100%) | Right        | 5 (100%) |
| Left pulmonary vein       | 8           | Left                              | 6 (75%)  | Left         | 4 (50%)  |
| Both pulmonary veins      | 5           | Left                              | 1 (12.5%) |              |        |
| Both                      |             | Both                              | 1 (12.5%) |              |        |

PAVMs, pulmonary arteriovenous malformations; TECE, transesophageal contrast echocardiography; CT, computed tomography.

relationship between a TECE grade scale and the presence of PAVMs on CT or pulmonary angiography findings.

We investigated the predictive value of TECE with the saline shunt test for identifying PAVMs in non-HHT patients who had symptoms associated with PAVMs, such as stroke, transient ischemic attack, or paroxysmal arterial embolism. We further analyzed TECE using the number of bubbles (grade scale), cardiac cycles, and shunt origin. Our findings suggest that TECE with a shunt test could safely be used as a screening test for PAVMs in non-HHT patients.

In this study, 387 (21.3%) of the 1,809 patients who received TECE with the agitated saline test showed positive findings. Of the 182 patients who underwent both TECE and an additional radiologic imaging study, 18 showed radiologic images compatible with PAVMs. Because TTCE detects PAVMs at a microscopic level (7, 24), which does not require embolization and is insignificant, it has a lower PPV than chest CT (6, 9). However, we also found that TECE (any grade) had low PPV (9.8%) even lower than that found in previous TTCE studies (6–9, 13, 22, 23). There are several possible explanations for this result. The previously reported TTCE studies were performed in patients with HHT, who have a PAVM prevalence between 30 and 50% (3, 25). The prevalence of PAVMs in the general population remains uncertain, but it has been estimated at approximately < 0.001% (26, 27). This result might explain why the PPV of this study is lower than in previous studies. Moreover, the lower the TECE grade scales, the more often they are microscopic level PAVMS that are undetectable on radiologic. Several studies about the diagnostic value of TTCE in PAVMs published that the lower TTCE grade scale was associated with a lower prevalence of radiologic detectable PAVM (9, 10). Since this study included relatively many patients with a small grade of TECE, low PPV was reported.

To improve the diagnostic value of TTCE for identifying PAVMs, several recent articles have reported an analysis system that uses grades and the onset of the cardiac cycle (6, 9, 22, 23). The number of bubbles in the LA is usually graded according to the grading system proposed by Barzilai et al. (28) and followed by Zukotynski et al. (29). An additional analysis is performed to prevent unnecessary radiation exposure. However, a grading system with more specific criteria is required to evaluate PAVMs in TECE, which shows high-resolution images, because of the relative non-objectivity of the previous system. We used a 4-grade scale according to the number of bubbles visible in the LA. We found that none of the patients with TECE grade 1 [\(N = 91\) (50%)] showed PAVMs on chest CT or pulmonary angiography. Comparing these results with the TTCE grades used by other authors, grade 1 in TTCE with a cut-off of 20 microbubbles was present in 35% of the patients in the study of Parra et al. (9) and 32% of the patients studied by Gazzaniha et al. (8). The PPV of different TECE grades for the presence of PAVMs on chest CT or pulmonary angiography was 10.6% for grade 2, 22.8% for grade 3, and 55.6% for grade 4. Also, among patients with TECE grades 2, 3, and 4 in this study, 4.3, 17.1, and 55.6%, respectively, had PAVMs requiring embolization. The relationships between the TTCE grades and the size of the afferent artery on chest CT were described in a previous study (9).

The present study has several limitations. First, among 1,809 subjects who underwent TECE, only half received both TECE and a further radiologic imaging study. One hundred ninety-four subjects did not undergo chest CT or pulmonary angiography based on the charge physician’s judgment. Our results might thus have been affected by selection bias. Second, because this study included only non-HHT patients with a suspected right to left shunt, only a few patients were finally diagnosed with a PAVM. Last, the grade scale for the TECE findings is a semi-quantitative method that can lead to interobserver variability.

**Conclusion**

This is the first study to report the use of TECE with the agitated saline test for diagnosing PAVMs. TECE with the agitated saline test is a reasonable screening test for identifying PAVMs in non-HHT patients with a suspected right to left shunt. TECE with a grade scale helps select patients with PAVMs that can be confirmed in chest CT or pulmonary angiography.
and require embolization. The grading scale could also help to reduce unnecessary radiation exposure from CT scans or pulmonary angiography in patients with small grade (< 10 bubbles) shunt in their TECE findings.

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

The studies involving human participants were reviewed and approved by the Institutional Review Board of Samsung Medical Center (IRB No. SMC 2021-11-120-001). Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

Author contributions

KHL, SMK, SJP, EKK, SAC, SCL, SWP, and YHC participated in the conception, design, analysis, interpretation of data, and drafting of the manuscript. All authors have approved it for publication.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcvm.2022.975901/full#supplementary-material

References

1. Cartin-Ceba R, Swanson KL, Krowka MJ. Pulmonary arteriovenous malformations. Chest. (2013) 144:1033–44.
2. Narshin KH, Ramaswamy R, Kinney TB. Management of pulmonary arteriovenous malformations in hereditary hemorrhagic telangiectasia patients. Semin Intervent Radiol. (2013) 30:408–12. doi: 10.1055/s-0033-1359736
3. Cottin V, Plauchu H, Bayle JY, Barthelet M, Revel D, Cordier JF. Pulmonary arteriovenous malformations in patients with hereditary hemorrhagic telangiectasia. Am J Respir Crit Care Med. (2004) 169:994–1000. doi: 10.1164/rccm.200310-1441OC
4. van Gent MW, Post MC, Snijder RJ, Westermann CJ, Plokker HW, Mager JJ. Real prevalence of pulmonary right-to-left shunt according to genotype in patients with hereditary hemorrhagic telangiectasia: A transthoracic contrast echocardiography study. Chest. (2010) 138:833–9. doi: 10.1378/chest.09-1849
5. Gossage JR, Kanj G. Pulmonary arteriovenous malformations. A state of the art review. Am J Respir Crit Care Med. (1998) 158:643–61.
6. Al-Saleh S, Dragulescu A, Manson D, Golding F, Tzabicsi J, Mei-Zahav M, et al. Utility of contrast echocardiography for pulmonary arteriovenous malformation screening in pediatric hereditary hemorrhagic telangiectasia. J Pediatr. (2012) 160:1039–43.e1.
7. van Gent MW, Post MC, Luermans JG, Snijder RJ, Westermann CJ, Plokker HW, et al. Screening for pulmonary arteriovenous malformations using transthoracic contrast echocardiography: A prospective study. Eur Respir J. (2009) 33:85–91. doi: 10.1183/09031936.0049008
8. Gazzaniga P, Buscarini E, Leandro G, Reduzzi L, Grosso M, Pongiglione G, et al. Contrast echocardiography for pulmonary arteriovenous malformations screening. Does any bubble matter? Eur J Echocardiogr. (2009) 10:513–8. doi: 10.1093/echojcd/jen317
9. Patra JA, Bueno J, Zarauza J, Farinas-Alvarez C, Cuesta JM, Ortiz R, et al. Graded contrast echocardiography in pulmonary arteriovenous malformations. Eur Respir J. (2010) 35:1279–85. doi: 10.1183/09031936.004309
10. Deng Y, Huang X, Wang G, Cao J, Wang S, Li Y, et al. Applicability of transthoracic contrast echocardiography for the diagnosis and treatment of idiopathic pulmonary arteriovenous malformations. Front Cardiovasc Med. (2021) 8:656702. doi: 10.3389/fcvm.2021.656702
11. Hsu CC, Kwan GN, Thompson SA, Evans-Barns H, van Driel ML. Embolisation for pulmonary arteriovenous malformation. Cochrane Database Syst Rev. (2012) 1:CD008017. doi: 10.1002/14651858.CD008017.pub5
12. Saboo SS, Chamathry M, Bhatta S, Park H, Sutphin P, Kay F, et al. Pulmonary arteriovenous malformations: Diagnosis. Cardiovasc Diagn Ther. (2018) 8:325–37.
13. Nanthakumar K, Graham AT, Robinson TI, Grande P, Pugash RA, Clarke JA, et al. Contrast echocardiography for detection of pulmonary arteriovenous malformations. Am Heart J. (2001) 141:243–6. doi: 10.1067/mhj.2001.112682
14. Soliman OJL, Geleijnse ML, Meijboom FJ, Nemes A, Kamp O, Nihoyannopoulos P, et al. The use of contrast echocardiography for the detection of cardiac shunts. Eur J Echocardiogr. (2007) 8:52–12. doi: 10.1016/j.euje.2007.03.006
15. Duch PM, Chandrasekaran K, Mulherin CB, Ross JJ Jr., MacMillan RM. Transesophageal echocardiographic diagnosis of pulmonary arteriovenous malformation. Role of contrast and pulsed Doppler echocardiography. Chest. (1994) 105:1604–5. doi: 10.1378/chest.105.5.1604
16. Vittala SS, Dameshchak RM, Huerli EA, Burke RE, Chaliki HP. Diagnosis of pulmonary arteriovenous malformation using a transeosophageal echocardiography bubble study. Eur J Echocardiogr. (2011) 12:664.
17. Zaidi SJ, Adhikari RR, Patel DR, Cui VW, Javois AJ, Roberson DA. Saline contrast transesophageal echocardiography in fontan patients: Assessment of the presence, type, and size of right to left shunts. Pediatr Cardiol. (2019) 40:1199–207. doi: 10.1007/s00246-019-02132-0
18. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. (2015) 28:1–39.e14. doi: 10.1016/j.echo.2014.10.003

19. Nagueh SF, Smiseth OA, Appleton CP, Byrd BF III, Dokainish H, Edvardsen T, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. (2016) 29:277–314. doi: 10.1016/j.echo.2016.01.011

20. Sondergaard L, Kasner SE, Rhodes JF, Andersen G, Iversen HK, Nielsen-Kudsk JE, et al. Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke. N Engl J Med. (2017) 377:1033–42. doi: 10.1056/NEJMoa1707404

21. Cummings KW, Bhalla S. Multidetector computed tomographic pulmonary angiography: Beyond acute pulmonary embolism. Radiol Clin North Am. (2010) 48:51–65. doi: 10.1016/j.rcl.2009.09.001

22. van Gent MWF, Post MC, Snijder RJ, Swaans MJ, Plokker HWM, Westermann CJJ, et al. Grading of pulmonary right-to-left shunt with transthoracic contrast echocardiography: Does it predict the indication for embolotherapy? Chest. (2009) 135:1286–92. doi: 10.1378/chest.08-1266

23. Fernandopulle N, Mertens I, Klingel M, Manson D, Ratjen F. Echocardiography grading for pulmonary arteriovenous malformation screening in children with hereditary hemorrhagic telangiectasia. J Pediatr. (2018) 195:288–91.e1. doi: 10.1016/j.jpeds.2017.11.047

24. Lee WL, Graham AF, Pugash RA, Hutchison SI, Grande P, Hyland RH, et al. Contrast echocardiography remains positive after treatment of pulmonary arteriovenous malformations. Chest. (2003) 123:351–8. doi: 10.1378/chest.123.2.351

25. Shovlin CL, Letarte M. Hereditary haemorrhagic telangiectasia and pulmonary arteriovenous malformations: Issues in clinical management and review of pathogenic mechanisms. Thorax. (1999) 54:714–29. doi: 10.1136/thx.54.8.714

26. Nakayama M, Nawa T, Chonan T, Endo K, Morikawa S, Bando M, et al. Prevalence of pulmonary arteriovenous malformations as estimated by low-dose thoracic CT screening. Intern Med. (2012) 51:1677–81. doi: 10.2169/internalmedicine.51.7703

27. Sloan RD, Cooley RN. Congenital pulmonary arteriovenous aneurysm. Am J Roentgenol Radium Ther Nucl Med. (1953) 70:183–210.

28. Barzilai B, Waggoner AD, Spessert C, Picus D, Goodenberger D. Two-dimensional contrast echocardiography in the detection and follow-up of congenital pulmonary arteriovenous malformations. Am J Cardiol. (1991) 68:1507–10. doi: 10.1016/0002-9149(91)90287-u

29. Zukotynski K, Chan RP, Chow CM, Cohen JH, Faughnan ME. Contrast echocardiography grading predicts pulmonary arteriovenous malformations on CT. Chest. (2007) 132:18–23. doi: 10.1378/chest.06-2356